Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of rBet v1-FV immunotherapy for birch pollen allergy
2007-001029-84Phase 3Completed
- Sponsor
- Allergopharma
- Start
- May 2007
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR) and birch pollen allergy comparing rBet v1-FV with Placebo (2 arms). Primary endpoint: Change in symptom medication score after 2 years of treatment. Started May 2007; status: completed.
02
Drugs
rBet v1-FV
03
Conditions
allergic rhinitis (AR)birch pollen allergy
Beyond the preview
Go deeper on 2007-001029-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001029-84.